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vs. 37%, p¼0.003). Of the 365 diabetics, 101 (27.6%) were ITDM. ITDM patients
were more often female (35.6% vs. 21.6, p¼0.006) and with a history of prior MI
(50.0% vs. 31.8%, p¼0.001) compared to NITDM. At 12-months follow-up, the
cumulative incidence of cardiac death, TLR and MI in patients with diabetes was
comparable to that of non-diabetics (3.7% vs. 5.0%, p¼0.417). The ITDM patients
demonstrated a higher, but non-signiﬁcant, incidence of the composite end-point
compared to NITDM (4.4% vs. 3.4%, p¼0.70). The incidence of deﬁnite/probable
stent thrombosis was similar between diabetics (2/365; 0.5%) and non diabetics (5/
851; 0.6%).
Conclusions: In this multicenter registry of patients suitable for PCI, the R-ZES
resulted as safe and effective in diabetic and non-diabetic patients at 1-year follow-up.
Among diabetics, patients with ITDM are associated with a higher, but not signiﬁcant,
incidence of adverse events than patients with NITDM.Variable N=385
Preprocedure
- Lesion length, mm 13.17 [8.97, 18.73]
- Reference diameter, mm 2.73 [2.43, 2.99]
- MLD, mm 0.74 [0.44, 1.02]
- %DS 72.2 [61.8, 83.8]
Postprocedure (in-stent analysis)
- MLD, mm 2.60 [2.31, 2.88]
- %DS 7.4 [4.7, 11.6]
- Acute gain, mm 1.88 [1.49, 2.24]TCT-211
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Background: The safety and efﬁcacy of stenting followed by delivery of paclitaxel
via balloon coating in comparison with stent-polymer matrix was not established.
Therefore we compared clinical and angiographic results of paclitaxel eluting stenting
(PES) with bare metal stenting and paclitaxel coated balloon post-dilation
(BMS+PCB) for de novo coronary lesions.
Methods: In this multicenter, prospective, non-inferiority trial 202 patients with stable
or unstable angina and at least one signiﬁcant coronary artery lesion (>50% diameter
stenosis, type A, B1 and B2) were randomized in 1:1 ratio to PCI with PES (Coroﬂex
Please, B.Braun) or BMS+PCB (Coroﬂex + Sequent Please, B.Braun). Clinical
follow-up was obtained at 9 months in all patients, whereas angiographic in a subset of
94.
Results: Patients baseline characteristics were well balanced between groups. At 9
months, in-stent late lumen loss in PCB+BMS were comparable and non-inferior to
PES (0.210.5 vs. 0.300.7mm respectively, pnon-inf<0.05). Clinically, the
incidence of MACCE (7.0 vs. 6.9%, HR¼1 95%CI:0.3-2.8; p¼0.99), comprising
of occurrence of myocardial infarction (4.9 vs. 3.0% HR¼1.62 95%CI:0.4-6.5;
p¼0.32), target lesion revascularization (6.9 vs. 5.0%, HR¼1.42 95%CI: 0.4-4.4;
p¼0.54) and stent thrombosis (ST: 5.9 vs. 3.8% HR¼2.01 95%CI: 0,5 to 7,4) was
similar between PCB+BMS and PES respectively. In PCB+BMS when compared
to PES most ST occurred early (5.0 vs. 1.0%; p¼0.10), whereas in PES - late (0.9
vs. 2.8% p¼0.18). There were no deaths or cerebro-vascular accidents in both
groups.
Conclusions: Revascularization strategy with PCB+BMS is an alternative to PES
with regard to neointimal hyperplasia, however the incidence of early ST raises safety
concerns.B68 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-212
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Background: The novel BioMime drug-eluting stent (Meril Life Sciences Pvt. Ltd.,
Gujarat, India) incorporates a L605 cobalt-chromium metallic platform that combines
ultra-thin struts (65mm) with hybrid cell design and a bioabsorbable co-polymer
(PLLA/PLGA) formulation (2mm thickness) which carries and releases sirolimus in
a dosage of 1.25mg per mm2 of stent surface area. Our objective was to report the
angiographic ﬁndings of the BioMime sirolimus-eluting stents (SES) tested in the
meriT-1 and -2 clinical trials.
Methods: 280 pts with 385 de novo lesions located in native vessels were prospec-
tively enrolled in 2 non-randomized studies in India, including the ﬁrst-in-man, single
center meriT-1 trial (30 patients/lesions) and the subsequent multicenter meriT-2 trial
(250 pts/355 lesions). Angiographic follow-up was assigned at 8 months. QCA
analysis was performed at an independent angiographic core lab.
Results: LAD was the target vessel in 47%, 16.4% had signiﬁcant calcium, 78.4%
were eccentric, 4.9% had ulcer and pre-TIMI ﬂow 3 was found in 87.5%. Most lesions
were classiﬁed as highly complex (type B2/C in 74.8%). Predilatation was performed
in 91%, the study stent was implanted in 100%, an additional study stent was
implanted in 6%, and 60% had postdilatation; also, ﬁnal TIMI 3 ﬂow was achieved in
99.5%. QCA results are shown in the Table. Binary restenosis was found in 5.7%
(4.5% in-stent) including focal pattern (type-I) in most cases (4.8%).Follow-up at 8 months (in-stent analysis) N¼335 (87%)
- MLD, mm 2.40 [2.05, 2.71]
- %DS 11.8 [7.4, 19.2]
- Late lumen loss, mm 0.12 [0.05, 0.30]Conclusions: In this subanalysis of the combined meriT-1 and -2 trials, the novel
BioMime SES demonstrated efﬁcacy in the treatment of complex de novo coronary
lesions, as demonstrated by the relatively low median in-stent late lumen loss (a
surrogate of neointimal hyperplasia) at 8-month angiographic follow-up (87%). In
addition, in-stent binary restenosis was low (<5%) and associated with focal pattern in
the majority of cases.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
